Susquehanna Fundamental Investments LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Susquehanna Fundamental Investments LLC acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 347,271 shares of the company's stock, valued at approximately $1,073,000. Susquehanna Fundamental Investments LLC owned approximately 0.32% of Tango Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TNGX. Virtus ETF Advisers LLC grew its stake in Tango Therapeutics by 127.1% in the fourth quarter. Virtus ETF Advisers LLC now owns 24,945 shares of the company's stock worth $77,000 after purchasing an additional 13,961 shares in the last quarter. Nebula Research & Development LLC raised its stake in Tango Therapeutics by 376.3% during the 4th quarter. Nebula Research & Development LLC now owns 51,924 shares of the company's stock valued at $160,000 after acquiring an additional 41,023 shares in the last quarter. Blue Owl Capital Holdings LP acquired a new position in Tango Therapeutics during the 4th quarter worth $5,352,000. Price T Rowe Associates Inc. MD grew its stake in shares of Tango Therapeutics by 29.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company's stock worth $65,000 after purchasing an additional 4,813 shares in the last quarter. Finally, TRV GP VI LLC acquired a new position in shares of Tango Therapeutics during the fourth quarter valued at $600,000. Hedge funds and other institutional investors own 78.99% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $13.00 price target on shares of Tango Therapeutics in a research report on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tango Therapeutics has an average rating of "Buy" and a consensus price target of $12.33.

Insider Buying and Selling at Tango Therapeutics

In other news, CEO Barbara Weber sold 9,778 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the sale, the chief executive officer now owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 24,268 shares of company stock worth $72,561 over the last three months. Company insiders own 6.30% of the company's stock.

Tango Therapeutics Trading Down 6.0 %

TNGX traded down $0.09 during midday trading on Monday, reaching $1.42. The company's stock had a trading volume of 508,318 shares, compared to its average volume of 1,078,791. Tango Therapeutics, Inc. has a twelve month low of $1.11 and a twelve month high of $12.02. The stock has a market cap of $153.51 million, a P/E ratio of -1.20 and a beta of 1.03. The company has a fifty day simple moving average of $1.60 and a 200 day simple moving average of $2.86.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The firm had revenue of $4.12 million for the quarter, compared to the consensus estimate of $7.84 million. Sell-side analysts expect that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.